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NF-κB transcription factors are dimers composed of five subunits belonging to the Rel family (20) . The five subunits of p65 (Rel A), Rel B, c-Rel, p50, and p52 can form various dimers (2, 23, 24) . The p50/p65 heterodimers are the best characterized and are the most abundant form of the NF-κB transcription factors in most cell types (8) . IκB is responsible for sequestering NF-κB in the cytoplasm by masking its nuclear localization signal (NLS) (3, 6, 9, 27) . Proteins that require nuclear translocation contain a NLS and are transported by importin α via its' interaction with the cargo's NLS (7, 16) . To date there have been six importin α family members identified (importin α1-6), all of which carry various cargo, including signal transducers and activators of trancription (STATs) and NF-κB (4, 11, 12, 17, 21) . Importantly, it was recently reported that TNFα-induced nuclear localization of p50/p65 heterodimers is mediated by importin α3 and importin α4 (5) . However, there have also been reports of importin α1 and importin α2 interacting with NF-κB, but their role in transport and activation remains unclear (5) . Because of the multifaceted nature of TNF-α and NF-κB, the NF-κB subunits and the importin α proteins have become prime targets of viruses to evade the outcome of inflammatory pathways.
Hantaviruses can cause two distinct types of human disease: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) (19) . Hantavirus associated diseases are thought to be immunologically mediated and there have been numerous reports of patients having elevated plasma levels of TNF-α during the acute phase of HFRS (13) (14) (15) . TNF-α positive cells can also be found in kidney and lung biopsies of HFRS and HPS patients. Clinically, hypotension and patient outcomes correlate with the levels of TNF-α (14, 15) .
Recently, studies, in addition to ours, suggest that hantaviruses can subvert innate immunity through several mechanisms. The Gc protein of the HPS-causing viruses, Andes virus (ANDV) and NY-1 virus (NY-1V) can inhibit activation of two important innate immune pathways, double stranded RNA (dsRNA) and interferon (IFN). NY-1V Gc has been shown to antagonize the activation of RIG-I, a protein involved in the induction of IFN (1) . ANDV Gc can inhibit the phosphorylation of transcription factors STAT1 and STAT2 and this was also shown in HTNV infected cells (22) . Furthermore, another HPS-causing hantavirus, Sin nombre virus, was also unable to induce production of IFN-α/β during infection (18) . Considering the clinical relevance of TNF-α during infection, we sought to determine if HTNV might also interfere with this inflammatory pathway.
HTNV N protein inhibits TNFα-induced activation of NF-κB. To date there have been no reports of studies examining the ability of HTNV to antagonize the TNF-α signaling pathway. To determine if the HTNV N, Gn, or Gc proteins could inhibit TNF-α-induced activation of NF-κB, a human NF-κB promoter that transcriptionally regulates the expression of GFP was used as a reporter. No GFP was detected in any of the samples that were left untreated indicating that the conditions of our experiment alone, including the presence of viral proteins, could not induce activation of NF-κB ( Fig. 1A and B ). HTNV N protein was able to inhibit transcriptional GFP expression from the NF-κB responsive promoter at all concentrations of TNF-α when compared to empty vector ( Fig 1A) . HTNV glycoproteins only had little effect on GFP expression suggesting that this phenomenon is N protein specific (Fig. 1A ). This inhibition occurred in a dose dependent manner but was still significantly less than the control empty vector ( Fig 1A) .
Proteosomal degradation of IκBα is required for the activation of NF-κB in the TNF-α pathway. In order to validate our assay, the proteosomal inhibitor MG132 was included as a control because it has been previously shown to inhibit this pathway. MG132 was also able to dramatically decrease the amount of GFP present in TNF-α treated cells and this was comparable to what we observed in cells expressing the HTNV S segment cDNA (Fig. 1A) .
We also examined whether TNF-α-induced activation of our reporter system correlated with the amount of viral protein or MG132 present in cells. As expected, increasing amounts of empty vector and HTNV glycoproteins had no effect on the expression of the NF-kB-GFP reporter (Fig. 1B) . However, inhibition of NF-kB-GFP was directly proportional to the amount of HTNV nucleocapsid and MG132 in cells, hence the greatest inhibition was observed with maximal N protein and MG132 present (Fig. 1B) . It should also be noted that expression of 6 the HTNV N and glycoprotein genes were not adversely affected by the amount or time that cells were treated with TNF-α (data not shown).
HTNV N protein inhibits activation of endogenous NF-κB p50 and p65. In order to validate the NF-κB reporter assay used above, we next examined whether HTNV N protein was able to inhibit activation of endogenous p50 and p65 subunits, the most abundant of the heterodimers used as an NF-kB transcription factor. To quantify NF-kB transcription factor activation, we employed an ELISA that measures binding to NF-kB consensus oligonucleotide sequences, followed by detection of p50 and p65 subunits with antibodies. As expected, there was little activation of transfected and untreated cells indicating that viral gene expression and transfection alone could not activate NF-kB proteins ( Fig. 2A) . In contrast, similar levels of activated p50 and p65 were detected from nuclear extracts of TNF-α stimulated cells that were transfected with empty vector or HTNV-M cDNA (Fig 2A) . Transfecting with HTNV -S cDNA significantly inhibited activation of p50 and p65 as determined with extracts of TNF-α stimulated cells and this was similar to what we observed with MG132 treated cells as compared to cells transfected with the empty vector ( Fig. 2A) . Although there was a small increase in activation of p50 and p65 in HTNV-S expressing cells treated with TNF-α as compared to untreated cells, this can most likely be explained by the fact that we were measuring activation of endogenous NF-kB in a total cell population, but not every cell was expressing the HTNV genes during the period of assay.
To confirm that cells were expressing viral genes, we prepared cytoplasmic extracts and examined them by immunoblotting to detect N protein ( Fig. 2B ) or by immunofluorescent antibody staining to detect Gn and Gc ( Fig. 3 ). Levels of the housekeeping protein GAPDH were also measured to rule out the possibility that the decreased inhibition we observed for HTNV N protein and MG132 treatment was not due to differences in the amount of lysate used in our assay ( Fig. 2B ).
HTNV nucleocapsid inhibits TNF-α -induced nuclear translocation of NF-κB p65. The transcription factor ELISA used above is not able to distinguish between inhibition due to reduced DNA binding or to the inability of NF-kB to enter the nucleus. To test whether cellular localization was altered in TNF-α-treated cells expressing HTNV -S, we performed an immunofluorescence assay. When localization and expression of p65 was examined by microscopy, all unstimulated and transfected or MG 132-treated cells had the expected cytoplasmic localization with no apparent differences in p65 protein expression within cells (Fig 3, upper panel) . In contrast, nuclear translocation of p65 was observed in cells transfected with empty vector or HTNV-M cDNA and treated with TNF-α ( Fig. 3 , lower panel, 1 st and 3 rd column). This indicates that there was no defect in the ability of p65 to move to the nucleus nor could transfection and viral gene expression alone inhibit this event. In contrast, TNF-α cells that were expressing HTNV-S cDNA had markedly reduced p65 that translocated to the nucleus ( Fig. 3 , lower panel, 2 nd column). As expected, treatment of cells with MG132 was also able to inhibit p65 from entering the nucleus (Fig. 3, lower panel, 4 th column). These data suggest that p65 is being sequestered in the cytoplasm by HTNV-N protein.
HTNV-S expression does not affect protein levels of p50 and p65 or degradation of IκB. Since it was difficult to definitively determine by microscopy whether the decreased nuclear p65 observed was due to retention in the cytoplasm or a decrease in the amount of total p65 present in cells expressing HTNV-S, we performed western blot analysis. No difference in the protein levels of p50 and p65 were observed in any of the samples that were transfected and unstimulated or stimulated with TNF-α ( Fig. 4 ). This indicates that the observed decrease in nuclear localization of p65 was probably due to the inability of NF-κB to enter the nucleus. β-Actin was used as a control to ensure equal loading of samples.
The TNF-α pathway requires the association of numerous signaling molecules such as TRADD, TRAF-2, and RIP and alteration of any of these molecules could inhibit activation of . The next question we wanted to address was whether the NF-κB proteins were being targeted directly by HTNV N protein or if a signaling molecule further upstream was being inhibited thus preventing activation of NF-κB. Since IκBα serves as an inhibitor of NF-κB and its degradation is required for translocation of activated NF-κB to the nucleus, we examined the ability of HTNV N protein to inhibit degradation of IκBα in the presence of TNF-α. Western blot analysis of IκBα levels demonstrated that TNF-α treatment was effective in subsequent degradation of IκBα in all transfected samples including HTNV-S segment expressing cells (Fig 4) . Furthermore, IκBα levels were similar in all unstimulated and transfected samples (Fig 4) .
HTNV N protein binds to nuclear import proteins, importin α. The above data suggest that NF-κB is being directly sequestered by HTNV N protein or has lost its ability to translocate to the nucleus. To examine if NF-κB was directly targeted we performed co-immunoprecipitation experiments to determine if HTNV N protein could interact with p50 or p65. No interaction was detected between HTNV N protein and NF-κB proteins nor did we detect any inhibition of the phosphorylation of NF-κB in the presence of HTNV N protein when treated with TNF-α (data not shown). These results suggest that transport of NF-κB was likely inhibited by HTNV N protein.
It has been reported that NF-κB accumulates in the nucleus via interaction of importin α3 and importin α4 and its nuclear localization signal. We next wanted to ask whether HTNV nucleocapsid could interact with these or possibly other importin α molecules. FLAG-tagged importin α1, importin α2, importin α3, or importin α4 were co-transfected with empty or HTNV-S expression plasmids. Immunoprecipitation with an anti-HTNV-N protein polyclonal antibody followed by western blotting with anti-FLAG antibody was used to detect importin α proteins. The results indicate that HTNV N protein is able to interact with importin α1, importin α2, and importin α3 and that the presence of TNF-α is not required for this interaction (Fig. 5 ). Western blotting of whole cell lysates demonstrated that there were similar levels of importin α and nucleocapsid protein in our samples.
HTNV inhibits TNF-α-induced nuclear localization of NF-κB p65 without affecting IκBα degradation. The HTNV S segment transfection experiments clearly demonstrated inhibition of NF-κB. To confirm that infection with HTNV also inhibits TNF-α-induced activation of NF-κB by preventing nuclear localization, we examined virus infected cells by immunofluorescent antibody staining with antibodies to p65 and HTNV N protein. We did not detect nuclear p65 in unstimulated cells that were mock-infected or infected with HTNV ( Fig. 6A, upper panel) . As expected, TNF-α stimulated mock-infected cells had predominantly nuclear localization of p65 ( Fig 6A, lower panel, 1 st column). Interestingly, as infection progressed to day 5, the staining pattern of p65 became predominantly cytoplasmic in TNF-α treated cells and this was similar to that of unstimulated cells ( Fig 6A, lower panel, 2 nd column).
To confirm that there was no decrease in the total protein levels of p50 or p65 and that no upstream signaling molecules were being targeted, we performed western blot analysis. Mock-infected or HTNV-infected lysates harvested after unstimulation or stimulation with TNF-α had no apparent differences in the overall levels of p50 or p65, indicating that this was not the cause of decreased nuclear localization in the presence of virus ( Fig  6B) . HTNV was also unable to inhibit degradation of IκBα after being treated with TNF-α, suggesting that IκBα itself and signaling molecules upstream are not being targeted by HTNV ( Fig. 6B ).
Preliminary results:
In addition to the results described above, we also began studies to define other innate immune evasion strategies. We focused on antagonism of the Type 1 interferon (IFN) system because it is usually the first line of defense against viral infections. Evasion of the IFN response by viruses can occur by preventing IFN release, inhibiting IFN-signaling and/or activity of IFN stimulated genes. To date there have been no reports of studies examining IFN antagonism of hantaviruses or of CCHFV. To examine this for hantaviruses, lung epithelial cells (A549) were mock-infected or infected with the HPS-causing hantavirus, Andes virus (ANDV), for 7 days and left untreated or treated with IFN every day. We determined by Real Time RT-PCR and western blot that the ANDV S segment synthesis and nucleocapsid production peak on day 4. We also examined the levels of phosphorylated STAT1 and STAT2 by western blot. In infected samples left untreated, little phosphorylated STAT1 and STAT2 was detected up to 4 days post infection. Beyond 4 days post infection, phosphorylated STATs were not detectable by western blot and immunofluorescence. In samples treated with IFN, ANDV was able to inhibit phosphorylation of STAT1 and STAT2 to the greatest extent starting on day 3 when compared to mock-infected cells. Furthermore, this inhibition was not a result of STAT1 or STAT2 being degraded. These data suggest that hantaviruses have the capability to subvert a host IFN response.
To examine IFN antagonism with CCHFV, 293T or HepG2 cells were mock-infected or infected with CCHFV for 5 days and left untreated or treated with IFN every day. We found that CCHFV activates the transcription factor IRF-3, thus allowing for transcription and production of IFN. The IFN made during infection retains its ability to activate STATs through the IFN signaling pathway and allows for upregulation of IFN stimulated genes. We did not detect any degradation of PKR, eIF2-alpha, or ISG15, all of which are upregulated by IFN. These results have led to examination of other arms of the innate immune and proinflammatory responses that could be inhibited.
KEY RESEARCH ACCOMPLISHMENTS:
• CCHFV possesses a novel evasion strategy that is mediated by the viral polymerase gene and results in deconjugation of ubiquitin and ISG15 from host proteins.
• HTNV nucleocapsid protein interferes with tumor necrosis factor alpha (TNF-α)-signaling for the induction of the NF-κB by binding to cellular transport proteins and preventing their use in moving TNF-α from the cytoplasm to the nucleus of infected cells. 2. Taylor, S. L., Firas-Staheli, N., Garcia-Sastre, A., and Schmaljohn, C.S. Hantaan virus nucleocapsid protein binds to importin α proteins and inhibits tumor necrosis factor-α -induced activation of nuclear factor kappa-b. Manuscript in preparation.
CONCLUSION:
We discovered two previously unknown mechanisms that hemorrhagic fever viruses use to subvert innate immunity by disrupting NF-κB signaling pathways. For CCHFV, we discovered a domain in the viral polymerase protein with the capacity to inhibit NF-κB-dependent signaling (ubiquitination) and to antagonize the antiviral effects of ISG15 in vivo. For HTNV we showed that the viral nucleocapsid protein binds to cellular transport molecules (importins), preventing the transport of TNF-α into the host cell nucleus. By sequestering TNF-α in the cytoplasm, HTNV prevents its use as a transcription factor to stimulate host genes involved in inflammatory and apoptosis processes. This is especially important since elevated levels of TNF-α are a hallmark of hantaviral diseases. We suspect that the ability of HTNV N protein to bind to cellular importins relates to a specific region of the gene that encodes a nuclear localization signal (NLS). We observed that similar or identical NLS sequences are present in the N genes of other hantaviruses, thus we are currently performing additional studies to determine if this is a common mechanism used by HFRS and HPS causing hantaviruses, and perhaps by other hemorrhagic fever causing viruses as well. In addition to these two new discoveries, we also demonstrated that the hantavirus, Andes virus, interfere with the in JAK-STAT pathway of interferon induction by inhibiting translocation of STAT1 and STAT2 to the nucleus.
In summary, we made new discoveries concerning how hemorrhagic fever viruses are able to evade host innate immunity. Further studies are needed to determine if these mechanisms are common to several viruses and if they can be overcome by exogenous interferon or other therapeutic means. 
APPENDICES:
FIGURE LEGENDS:
Fig. 1 The effect of HTNV N protein on NF-κB gene expression. (A)
293T cells were co-transfected with 500 ng of pNF-κB-hrGFP and 500 ng of either pWRG7077-Empty, pWRG7077-HTNV-S or pWRG7077-HTNV-M. After 24 h, cells were incubated in medium with or without TNF-α (0 to 100 ng/ml) for 4 h. As a positive control for inhibition in our assay, cells transfected with only 500 ng of pNF-κB-hrGFP were pretreated with 50 µM MG132 for 2 h before the addition of TNF-α and throughout the experiment. (B) Cells were co-transfected with 500 ng of pNF-κB-hrGFP and 5-500 ng of either pWRG7077-Empty, pWRG7077-HTNV-S or pWRG7077-HTNV-M. Or transfected with 500 ng of pNF-κB-hrGFP and treated with 0-50 µM MG132. After 24 h, cells were incubated in medium with or without TNF-α (10 ng/ml) for 4 h. After 4 h of treatment, medium was removed from all wells and replaced with medium lacking TNF-α for an additional 24 h. GFP expression was examined by fluorescence microscopy.
Fig. 2 Endogenous NF-κB transcription activation in cells expressing HTNV-S segment cDNA.
A549 cells were transfected with 500 ng of pWRG7077-Empty, pWRG7077-HTNV-S, or pWRG7077-HTNV-M for 24 h. After treating the cells with 50 ng/ml of TNF-α for 15 min, cytoplasmic and nuclear extracts were prepared from lysates. (A) Nuclear extracts were allowed to bind to NF-κB consensus sequence oligos on 96-well plates followed by probing with antibodies specific for NF-κB p65 or NF-κB p50. Absorbance reading for each sample was determined using a spectrophotometer. (B) Cytoplasmic extracts were used for immunobloting to detect HTNV N protein and GAPDH. Statistical significance of the wild-type oligo+TNF was determined by comparing to the MUT oligo+TNF. Significance of N protein+TNF and MG132+TNF was determined by comparing to empty vector + TNF .
Fig. 3 Intracellular localization of NF-κB p65 in HTNV-S segment expressing cells. A549 cells were
transfected with 500 ng of pWRG7077-Empty, pWRG7077-HTNV-S, pWRG7077-HTNV-M for 24 h. As a control for inhibition of nuclear translocation, some cells were pretreated with MG132 for 2 h before stimulation with TNF-α. After incubation, cells were left untreated or treated with 50 ng/ml of TNF-α for 15 min and fixed and stained with antibodies against NF-κB p65 (green), HTNV N or Gc? proteins (red) and stained with DAPI to highlight nuclei (blue).
Fig. 4 Examination of TNF-α-induced IκBα degradation and NF-κ B p50 and p65 levels in HTNV-S segment expressing cells.
A549 cells were transfected with 500 ng of pWRG7077-Empty, pWRG7077-HTNV-S, or pWRG7077-HTNV-M for 24 h. To induce degradation of IκBα, cells were treated with 50 ng/ml of TNF-α for 15 min and lysates were prepared for immunoblotting. For un-induced samples, cells were left untreated. Proteins were transferred to PVDF membranes and probed with antibodies against IκBα, p50, p65, HTNV N protein, or GAPDH. 
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INTRODUCTION
Viruses have evolved a panoply of different mechanisms to subvert cellular processes to their own advantage. In par-ticular, viruses must overcome the potent antiviral and inflammatory effects of innate immune cytokines such as type I interferon (IFNab) and tumor necrosis factor alpha (TNFa). The induction and activity of these antiviral cytokines is controlled by, among other factors, Ub and Ublike (UBL) molecules (Kirkin and Dikic, 2007) . The activation of the transcriptional regulator nuclear factor-kB (NF-kB) by TNFa was one of the first immune regulatory pathways found to be dependent on protein ubiquitination (Karin and Ben-Neriah, 2000) . NF-kB is sequestered in the cytoplasm of unstimulated cells through binding to IkB. TNFa binding to its receptor induces IkB phosphorylation followed by K 48 -linked poly-ubiquitination targeting IkB for proteasomal degradation. This releases NF-kB dimers for translocation to the nucleus, where they regulate transcription. NF-kB-induced genes include type I IFN and other cytokines, hence this Ub-controlled pathway plays a vital role in innate and adaptive immunity, as well as in inflammation (Tergaonkar, 2006) . In addition to ubiquitination of IkB, K 63and K 48 -linked ubiquitination regulates other molecules involved in this signaling pathway (Chen, 2005) . ISG15 is an interferon-induced UBL molecule with important antiviral activity against Sindbis, herpes simplex, influenza A, and influenza B viruses (Lenschow et al., 2007) . ISG15, like Ub, is covalently conjugated to target proteins via a C-terminal LRLRGG sequence (Haas et al., 1987; Loeb and Haas, 1992; Narasimhan et al., 1996) . Although conjugation is critical for the antiviral activity of ISG15 (Lenschow et al., , 2007 , the mechanism by which ISG15 mediates its antiviral function is not completely understood.
Ub and ISG15 are synthesized as inactive precursors with C-terminal extensions that undergo cleavage to reveal the motif required for conjugation. Coordinated activities of an enzymatic cascade comprising an activating enzyme (E1), a conjugating enzyme (E2) and a ligase (E3) result in the conjugation of Ub or ISG15 to the 3-amino group of a lysine residue present in the target protein.
Both Ub and ISG15 conjugation can be reversed by the activity of deconjugating enzymes. Deubiquitinating (DUB) proteolytic enzymes are also involved in processing of Ub precursors. Five classes of DUBs have been described (Nijman et al., 2005) ; one of the most recently identified is the ovarian tumor (OTU) domain family. This family comprises a group of putative cysteine proteases, homologous to the OTU protein in Drosophila, and includes more than a hundred proteins from eukaryotes, bacteria, and viruses (Makarova et al., 2000) . Several OTU domain-containing mammalian proteins, such as Cezanne (Evans et al., 2003) , Otubain 1 and 2 (Balakirev et al., 2003) , and A20 (Evans et al., 2004) have been identified as proteases that participate in substrate-specific deubiquitinating processes. For example, A20 is an important downregulator of TNFa signaling via its deubiquitination of TRAF6 and its dual function of poly-Ub 63 deconjugation followed by poly-Ub 48 modification of RIP (Wertz et al., 2004) . These activities are mediated by its N-terminal OTU domain and its C-terminal zinc finger domain, respectively. However, the substrate specificity and physiologic role of most OTU domaincontaining proteins remains unknown.
As protein ubiquitination and ISGylation are both important for innate immunity, rely on terminal LRLRGG sequences, and share a common mechanism of conjugation, we tested the hypothesis that viral OTU domain-containing proteases regulate Ub-and ISG15-dependent innate immunity via deconjugating protease activity. We found that two unrelated families of RNA viruses express OTU domain-containing proteases with the capacity to decrease Ub and ISG15 conjugation. Nairoviruses are negative-sense, segmented, RNA viruses of the Bunyaviridae family. Their large (L) protein contains an OTU domain and an RNA polymerase domain, placing this protein in the growing category of multifunctional viral proteins. Crimean Congo hemorrhagic fever virus (CCHFV) is a human nairovirus that causes hemorrhagic fever with up to 30% mortality (Whitehouse, 2004) . Arteriviruses, including equine arteritis virus (EAV) and porcine respiratory and reproductive syndrome virus (PRRSV), are the causative agents of important diseases in horses and pigs. They are positive-sense, nonsegmented RNA viruses that contain an OTU domain within their nonstructural protein 2 (nsp2), which is also involved in viral replicase polyprotein processing (Snijder et al., 1995) . We found that these viral OTU domains, in contrast to known mammalian OTU proteases, display a broad deconjugating activity toward ubiquitinated and ISGylated products and consequently inhibit innate immunity pathways that are dependent on Ub and ISG15. Thus, the deconjugating activity of viral OTU domains represents a unique strategy used by nairoviruses and arteriviruses to evade the host antiviral response, probably by targeting a common biochemical structure in Ub and the UBL protein ISG15.
RESULTS
OTU Domains in Viral and Mammalian Proteins
Sequencing of the L gene of the highly pathogenic human virus CCHFV (NFS and AGS, data not shown) (Honig et al., 2004; Kinsella et al., 2004) led to the identification of an OTU domain in the N-terminal region of the viral protein (Figure 1) . This domain was also present in the L proteins of the nairoviruses Dugbe virus (DUGV) and Nairobi sheep disease virus (Honig et al., 2004) but has not been found in the L proteins of any other genus in the Bunyaviridae family. An alignment of the OTU domains present in nairoviruses, arteriviruses, and mammalian proteins A20, Cezanne, VCIP135, Otubain 1, and Otubain 2 revealed limited identity; however, a strong conservation of D 37 , G 38 , N 39 , C 40 , W 71 , H 151 , and an aromatic amino acid at position 152 (numbering based on the CCHFV-L sequence) was observed (Figure 1, black boxes) . Among these amino acids, C 40 and H 151 (Figure 1, black arrows) were predicted to be the catalytic residues present in the putative protease active site (Balakirev et al., 2003; Makarova et al., 2000; Nanao et al., 2004; Snijder et al., 1995) .
Impact of CCHFV-L Expression on Protein Ubiquitination and ISGylation
Given that host OTU domain proteins have deubiquitinating activity (Nijman et al., 2005) , we tested the hypothesis that the L protein of CCHFV (CCHFV-L) has deubiquitinating and deISGylating activity (Figure 2 ). Transfection of 
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Evasion of Ubiquitin-and ISG15-Dependent Immunity cells with plasmids expressing CCHFV-L slightly decreased the overall expression of Ub-conjugated proteins ( Figure 2B, lanes 1 and 2, panel A; Figure 2C, lanes 1, 4,  and 5, panel A) . To test the effect of CCHFV-L expression on protein ISGylation, ISG15 conjugates were generated by transfecting plasmids expressing ISG15 and its specific E1 (UBE1L) (Yuan and Krug, 2001 ) and E2 (UbcM8) (Kim et al., 2004; Zhao et al., 2004) enzymes, since endogenous levels of ISGylated proteins are low in the absence of IFN stimulation. Cotransfection of CCHFV-L resulted in a clear decrease in the level of ISGylated proteins ( Figure 2B,  lanes 1 and 2, panel B ; Figure 2C, lanes 1, 4, and 5, panel  B ). This decrease was also observed when CCHFV-L was untagged (data not shown). The decrease in total ISGylation was comparable to the effect of UBP43, a known ISG15 deconjugating enzyme ( Figure 2B, lane 9, panel B) . Expression of CCHFV-L did not affect levels of expression of UBE1L or UbcM8 ( Figure 2B , lane 2, panels C and D; Figure 2C , lanes 4 and 5, panel C), consistent with CCHFV-L acting via inhibition of ubiquitination and ISGylation reactions or by directly deubiquitinating or deISGylating proteins.
The OTU Domain of CCHFV-L Decreases the Levels of Ubiquitinated and ISGylated Proteins
To determine the region of the L protein responsible for decreasing ubiquitinated and ISGylated proteins, plasmids expressing three portions of the L protein were constructed (Figure 2A) . Expression of the OTU domaincontaining N-terminal portion, L(1-1325), resulted in the greatest decrease of Ub and ISG15 conjugates (Figure 2B, lane 3, panels A and B) . To further map this region, truncation mutants of the L protein expressing only the first 354, L(1-354), or 169 amino acids, L(1-169), were tested. The results indicated that the region responsible for the decreased levels of Ub and ISG15 conjugates mapped to the OTU domain, L-(1-169) (Figure 2B, lanes 6 and 7, panels A and B ; Figure 2C , lane 2, panels A and B).
The Predicted Protease Active Site of the CCHFV-L OTU Domain Is Required for Reducing Ub and ISG15 Conjugates
To test whether the amino acids C 40 and H 151 (Figure 1 , black arrows) were critical for the observed reduction in ubiquitinated and ISGylated proteins by the CCHFV-L OTU domain, we expressed a full-length L protein with a C 40 to A 40 mutation (L 1A) and a mutant L(1-169) protein in which both amino acids were replaced by alanines [L(1-169)2A] (Figure 2A ). Expression of L 1A and L(1-169)2A proteins did not decrease levels of ubiquitinated or ISGylated proteins ( Figure 2B, lane 8, panels A and B ; Figure 2C, lanes 3, 6, and 7, panels A and B) , strongly suggesting that the OTU domain contains a cysteine protease activity that mediates the decrease in ubiquitinated and IS-Gylated proteins.
The OTU Domain of CCHFV-L Is a Deconjugating Enzyme with Specificity for Poly-Ub Conjugates and ISG15
To determine whether the CCHFV-L OTU domain directly deconjugates Ub and ISG15 from target proteins, we expressed and purified L(1-169) and a catalytic C 40 to A 40 mutant, L(1-169)1A, for in vitro deconjugation assays (Figure 3A) . Recombinant L(1-169) cleaved both K 48 -and K 63linked poly-Ub chains into monomers ( Figure 3B , lanes 2 to 5), similarly to isopeptidase T, a known DUB enzyme ( Figure 3B, lane 10) . This activity was markedly decreased by mutating the amino acid C 40 ( Figure 3B, lanes 6 to 9) , indicating that this residue is required for optimal protease activity. The small amount of deconjugation observed with L(1-169)1A is not unexpected, as mutation of Cezanne's catalytic cysteine yielded similar data where most, but not all, catalytic activity was impaired (Evans et al., 2003) . This result shows that the OTU domain of CCHFV-L has bona fide DUB activity in the absence of other cellular proteins.
We next determined whether L(1-169) can deconjugate ISGylated proteins. For this, we generated cell lysates from IFNb-treated Ubp43 À/À murine embryonic fibroblasts (MEFs) that are rich in ISG15 conjugates (Malakhov et al., 2003) . Incubation of these lysates with recombinant L(1-169) protein, but not L(1-169)1A, appreciably decreased ISGylated proteins ( Figure 3C , top panel) in a L(1-169) concentration-dependent manner. This result suggests that the CCHFV OTU domain has C 40 -dependent ISG15 deconjugating activity but does not exclude the possibility that the protease activity of the viral OTU domain was activating another deISGylating enzyme present in cell lysates. To address this possibility, we enriched 6xHisISG15 conjugates using affinity chromatography. Incubation of ISG15 conjugates with increasing amounts of L(1-169) resulted in ISG15 deconjugation ( Figure 3C , lanes 2 to 5, bottom panel). No deconjugation was detected with the mutant L(1-169)1A protein ( Figure 3C, lanes 6 to 9, bottom panel) . In addition, L(1-169) processed a pro-ISG15 protein into its mature form ( Figure 3E, lane 2, panel A) . These data suggest that the CCHFV-L OTU domain directly deconjugates IS-Gylated proteins through its predicted cysteine protease activity.
To gain further insights on the specificity of the OTU domain, we assessed the ability of L(1-169) and L(1-169)1A to hydrolyze poly-SUMO-2 ( Figure 3D, top panel) and poly-SUMO-3 chains ( Figure 3D, bottom panel) , pro-SUMO-1 ( Figure 3E, panel C) , and pro-Nedd8 ( Figure 3E,  panel B ). While the catalytic domain of SENP2 (SENP2 CD ), a SUMO-specific protease, could hydrolyze SUMO chains to monomers ( Figure 3D, lane 10) and process pro-SUMO-1 ( Figure 3E , lane 5, panel C), neither L(1-169) nor L(1-169)1A was able to cleave SUMO chains or a pro-SUMO-1 precursor. However, similar to its ability to process pro-ISG15 ( Figure 3E, lane 2, 
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Additional Viral OTU Domains Mediate Deubiquitination and DeISGylation
In addition to CCHFV, viral OTU domains are found in the L proteins of other nairoviruses and in the nsp2 proteins of arteriviruses such as EAV and PRRSV (Figure 1) . The arterivirus nsp2 cysteine protease cleaves the nsp2/nsp3 site within the large viral polyprotein during replicase maturation. In the case of EAV, this process is known to be mediated by the 166 N-terminal residues of nsp2, which contains the OTU domain (Snijder et al., 1995) . In our study, a slightly larger N-terminal EAV-nsp2 domain (175 amino acids; nsp2N) was used in addition to the fulllength protein. The OTU domain of the L protein of DUGV, a nairovirus related to CCHFV, as well as EAV-nsp2, EAV-nsp2N, and PRRSV-nsp2, decreased Ub and ISG15 conjugates when expressed in 293T cells ( Figure 4A , lanes [3] [4] [5] [6] , indicating that deconjugation may be an immune evasion strategy shared by diverse viral families.
Previous studies have demonstrated that the OTU domain-containing mammalian proteins Otubain 1, Otubain 2, Cezanne, VCIP135, and A20 cleave poly-Ub chains in vitro (Balakirev et al., 2003; Evans et al., 2003 Evans et al., , 2004 Wang et al., 2004) . In contrast, only overexpression of Otubain 1 and Cezanne moderately decreased cellular global Ub conjugate levels, while expression of A20 or Otubain 2 had no effect on total levels of ubiquitinated proteins (Balakirev et al., 2003; Evans et al., 2003 Evans et al., , 2004 . To date, there have been no published studies investigating the effects of these proteins on ISG15 conjugates. We therefore tested Otubain 1, Otubain 2, Cezanne, VCIP135, and A20 for their ability to decrease overall protein ubiquitination and ISGylation in transfected cells ( Figure 4B ). Expression of Otubain 1 resulted in a significant decrease in Ub conjugate levels, while Otubain 2 and Cezanne had a lesser effect ( Figure 4B, lanes 2-4, panel 1 ). Consistent with their specificity for particular ubiquitinated substrates, expression of VCIP135 and A20 did not result in a decrease in overall ubiquitination. None of the OTU-containing mammalian proteins tested decreased global levels of ISG15 conjugates ( Figure 4B, lanes 2-6, panel 2) . Similar results were obtained when truncation mutants expressing the OTU domains of Otubain 1, Otubain 2, Cezanne, and A20 were tested (data not shown). In addition, the OTUcontaining catalytic domain of A20 (A20 CD ) was unable to process either ISG15 or Nedd8 ( Figure 3E, lane 4,  panels A and B) , even though it cleaved K 48 -linked Ub chains ( Figure 3F, lane 4) . By contrast, overexpression of the mammalian deISGylating enzyme UBP43 decreased overall levels of ISG15 conjugates but not Ub conjugates ( Figure 4B, lane 7) . Thus, viral OTU proteases appear to be unique in their ability to target both ISG15 and Ub conjugates.
Transgenic Mice Expressing CCHFV-L(1-1325) Have Increased Susceptibility to Sindbis Virus Infection
To assess the effect of expressing an OTU domain during viral infection, we generated transgenic mice expressing the CCHFV-L(1-1325) OTU domain-containing protein, which exhibits DUB and deISGylating activities ( Figure 2B, lane 3) . We obtained germline transgene transmission in three lines designated 1836, 1854, and 2929, and we evaluated L(1-1325) expression in both MEFs and brain lysates from these transgenic lines. MEF cells and brain tissue from 1836 transgenic mice contained detectable L(1-1325) protein, while protein expression from the 1854 and 2929 lines was either undetectable or very low (Figures 5A and 5B) . We next evaluated the 
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Evasion of Ubiquitin-and ISG15-Dependent Immunity sensitivity of L(1-1325) transgenic mice to infection with the virulent Sindbis virus strain AR86, an alphavirus that causes lethal encephalitis in young mice and is sensitive to ISG15-mediated antiviral effects . Susceptibility to Sindbis virus infection tracked with expression of the L(1-1325) protein ( Figure 5C ). Thirty-five percent of mice from the 1836 transgenic line survived infection compared to R80% survival in C57/BL6 littermate controls or transgenic mice expressing low or undetectable levels of transgene-encoded protein. The decreased survival of line 1836 transgenic mice following AR86 infection suggests that CCHFV-L OTU enhances susceptibility to viral disease in vivo.
The OTU Domain of CCHFV Overcomes ISG15-Mediated Protection from Sindbis Virus-Induced Lethality
The increased pathogenicity of Sindbis virus observed in L(1-1325)-expressing mice suggested that the CCHFV-L OTU domain might counteract the antiviral activities of ISG15 in vivo. It was previously shown that expression of ISG15 from the chimeric Sindbis virus dsTE12Q protects adult IFNabR À/À mice from Sindbis virus-induced lethality . To determine whether expression of the CCHFV-L OTU domain would antagonize this protective effect of ISG15, we engineered four recombinant chimeric Sindbis viruses ( Figure 6A ). Two viruses expressed ISG15 followed by an IRES element to drive translation of either L(1-169) (169GG) or enzymatically inactive L(1-169)2A (MTGG). We also generated control viruses that expressed either L(1-169) (169) or L(1-169)2A (MT) in the absence of ISG15.
The recombinant viruses expressed the OTU domains and ISG15 as expected (Figures S1A and S1B in the Supplemental Data available with this article online) as well as similar levels of Sindbis virus proteins in infected cells ( Figure S1C ). All four viruses grew with similar kinetics to similar final titers under single-step growth conditions in BHK-21 cells ( Figure S2) . This is expected, as to date ISG15 has only demonstrated antiviral activity in vivo.
We assessed the ability of the L(1-169) protein expressed from within the Sindbis virus genome to deISGylate and deubiquitinate proteins by infecting BHK-21 cells ( Figure 6B ). Infection with 169GG or 169, but not MTGG or MT, reduced the amount of Ub conjugates detected in cells ( Figure 6B, right panel) , indicating that the viral OTU domain functions as a DUB enzyme when expressed from a Sindbis virus. Following transfection with ISG15 and its E1, E2, and E3 enzymes, ISGylated proteins can be detected in BHK-21 cells ( Figure 6B, lane 1, middle  panel) . Infection with 169GG or 169 greatly reduced ISG15 conjugates, confirming that OTU expression results in deconjugation of ISGylated proteins. When cells were transfected with the E1, E2, and E3 enzymes but not ISG15, ISG15 conjugates were observed only following MTGG infection ( Figure 6B, left panel) . This shows that ISG15 expressed from dsTE12Q is capable of ISGylating proteins in the presence of the relevant conjugating enzymes but that this is only seen in the presence of a catalytically inactive form of the coexpressed L(1-169) protein ( Figure 6B, lane 3, left panel) .
We then determined whether OTU expression could counter ISG15's in vivo antiviral effect. In order to exclude effects due to IFNab-stimulated genes other than ISG15, we infected IFNabR À/À mice ( Figure 6C ). Seventy percent of mice infected with a virus expressing ISG15 and the mutant OTU domain (MTGG) survived, consistent with previous observations that expression of ISG15 protects mice from lethality following Sindbis virus infection . In contrast, only 20% of mice infected with a virus expressing ISG15 and a functional OTU domain (169GG) survived infection (p = 0.0015). These data also correlate with our in vitro data demonstrating that L(1-169), but not L(1-169)2A, can deISGylate proteins following infection ( Figure 6B ). Mice infected with 169 or MT died with similar kinetics, demonstrating that the expression of L(1-169) did not increase the virulence of dsTE12Q in the absence of the IFN-mediated antiviral response. The slight increase in survival between 169GG and 169 (p < 0.0001) or MT (p = 0.0032) suggests that 
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Negative Regulation of the NF-kB Pathway by Viral OTU Domains
While the data above indicate that a viral OTU domain protease can counter the antiviral activities of ISG15, they do not address the possibility that the DUB activity of these proteins might also play a role in immune evasion. To address this hypothesis, we evaluated the effects of the CCHFV-L and EAV-nsp2 OTU domains on the NF-kB signaling pathway. Expression of the OTU domains of CCHFV-L and of EAV-nsp2 decreased in a dose-dependent manner the activation of an NF-kBresponsive promoter (Fujita et al., 1992) after TNFa treatment. This inhibition was similar to that mediated by A20, an OTU domain-containing inhibitor of the NF-kB pathway ( Figure 7A) . Inhibition was about 10-fold greater in the presence of the L(1-169) domain than the L(1-169)2A mutant, indicating a role for the OTU domain protease activity. These results were further confirmed by the ability of CCHFV-L(1-169) to inhibit NF-kB activation as measured by the inhibition of endogenous p65 nuclear translocation upon TNFa treatment ( Figures 7B and 7C) . The slight inhibition of NF-kB activation by the L(1-169)2A protein could be caused by some residual binding of this mutant to ubiquitinated substrates or by the presence of some other regulatory motifs within this protein. Nevertheless, the p65 nuclear translocation inhibition by the L(1-169) protein was significantly higher when compared to its mutant counterpart (p = 0.0044). Overall, these results demonstrate the ability of viral OTU domains to affect immune pathways that are regulated by ubiquitination.
DISCUSSION
Here we show that viral OTU domain-containing proteins are proteases that hydrolyze Ub and ISG15 from conjugated proteins. This dual deconjugating activity provide an elegant example of the economy of viral evolution, since both Ub and ISG15 rely on a conserved conjugation motif. Furthermore, the protease activity by the viral OTU domains has the physiologic capacity to evade two different cytokine pathways, IFNab and TNFa, that are fundamentally important for antiviral immunity. Biochemical and genetic evidence supports the concept that protein ubiquitination plays a critical role in the induction of both the innate and the adaptive cellular immune system (Liu et al., 2005) . For example, in addition to NF-kB signaling, Ub regulates several aspects of antiviral immunity, such as MHC class I and II antigen presentation (Loureiro and Ploegh, 2006; Shin et al., 2006) , TLR/IL1 signaling (Chen, 2005) , and induction of type I IFN by the cellular viral sensor RIGI (Gack et al., 2007) . Inhibition of protein ubiquitination might also affect other cellular processes that can be subverted by viruses for their own advantage, such as the proteasome-mediated protein degradation system, multiple signal transduction events, or cell cycle progression. Given the effects that we observed on NF-kB signaling, it seems likely that viral OTU domain-containing proteases may be able to target these and other Ub-dependent pathways.
While the biochemical effects of ISGylation have been studied far less extensively than those of Ub, ISG15 is an important antiviral protein (Lenschow et al., , 2007 Okumura et al., 2006) . Thus, it is not surprising that viruses may use multiple strategies to counter the antiviral effects of ISG15. The work presented here provides a viral strategy for decreasing expression of bona fide ISG15 conjugates in cells. The first such strategy reported is the direct association of the NS1 protein of influenza B virus with ISG15. This association inhibits protein ISGylation by blocking the ISG15-UBE1L interaction (Yuan et al., 2002 ; Yuan and Krug, 2001) , while the viral OTU domain proteases analyzed here accomplish a similar effect via deconjugation.
The Ub and ISG15 deconjugation activities by the viral OTU domains contrast with the specific Ub deconjugation activity by the OTU domain-containing cellular proteins tested in this study. We speculate that other viral proteases, perhaps including some that do not have OTU domains, will be found to target both Ub-and ISG15-dependent processes. To date, viral DUB activities and in vitro cleavage of ISG15 fusion proteins have been demonstrated for the adenoviral protease adenain (Balakirev et al., 2002) and the papain-like proteases from the severe acute respiratory syndrome coronavirus (SARS-CoV) (Barretto et al., 2005; Lindner et al., 2005; Ratia et al., 2006) .
OTU Domain Specificity and Deconjugating Activity, a Target for Antiviral Drug Development?
We found that the CCHFV-L OTU domain processed Ub and ISG15 conjugates and pro-ISG15 and pro-Nedd8 in vitro but did not have activity against any SUMO isoforms. Ub, ISG15, and Nedd8 differ from SUMO in their exposed C-terminal motifs: LRLRGG for Ub and ISG15 and LALRGG for Nedd8 versus QQQTGG for SUMO-2 and SUMO-3. This raises the interesting possibility that sequences similar to the LRLRGG motif may play an important role in substrate recognition and specific cleavage by CCHFV-L OTU and perhaps other viral proteases. Interestingly, the nsp2 of arteriviruses cleaves the nsp2/3 junction at FRLIGG (EAV) or GRLLGG (PRSSV) (Allende et al., 1999; Snijder et al., 1996; Ziebuhr et al., 2000) , sequences similar to the LRLRGG motif. Thus, arterivirus OTU proteases have dual functions: performing essential viral polyprotein processing and targeting host substrates to modulate the antiviral response. This is analogous to the hepatitis C virus NS3-4A protease, which is involved both in viral polyprotein processing and in cleaving the cellular antiviral proteins TRIF and IPS-1 Lin et al., 2006) .
The characterization of the CCHFV-L OTU domain and the development of in vitro assays for its enzymatic activities as described in this study will make it feasible to screen for potential inhibitors specific for CCHFV-L and other OTU domain-containing viral proteins. High-throughput screening of chemical compound libraries has proven to be a valuable tool in the identification of small-molecule inhibitors of other viral proteases such as HCV-NS3-4A (Sudo et al., 2005) and SARS-3CLpro (Blanchard et al., 2004) . Since the viral OTU domains have a unique capacity to target both Ub and ISG15 conjugates, the design of specific inhibitors might be possible. For this reason, structural studies will be of great value to understand both the molecular basis of the unique biochemical activities of these viral proteins and the potential for development of antiviral compounds.
Physiologic Importance of Viral OTU Domain Protease DUB and DeISGylating Activities Our demonstration that viral OTU domain-containing proteases can decrease both Ub and ISG15 conjugates in cells does not alone constitute proof that protease activity directed toward these substrates plays a role in viral infection. We were limited in performing the obvious experiment of assessing the role of viral OTU domain protease activity during infection by two things. First, CCHFV is a biosafety level 4 pathogen lacking a good animal model and whose molecular biology is not well enough developed to allow generation of mutant viruses. Second, the viral OTU domain proteases evaluated here either have, or are likely to have, important effects on processing of viral polyproteins (see above). Given this, we felt that it would be difficult to prove that these proteases have effects during infection that are solely attributable to their DUB and deISGylating activities. However, in transgenic mice, recombinant chimeric Sindbis viruses, and transfected cells, we found that viral OTU domain-containing proteases have significant effects on Ub-and ISG15-dependent host processes of known importance for innate immunity. We therefore conclude that these proteins have bona fide immune evasion properties. It will be interesting to further investigate the activities of these and other viral proteases that target Ub-and ISG15-dependent processes during viral infection.
EXPERIMENTAL PROCEDURES Expression Plasmids
Plasmids pCAGGS-6HismISG15, pCAGGS-hUBE1L-HA, pFLAGCMV2-UbcM8, and pcDNA3.1-UbcM8 were provided by Dong-Er Zhang (Scripps Research Institute, La Jolla, CA) . Herc5 was provided by Motoaki Ohtsubo (Kurume University, Fukuokaken, Japan). pcDNA 3.1 + -HA-Ub was provided by Dr. Domenico Tortorella (Mount Sinai School of Medicine, NY) (Treier et al., 1994) . Peak10-Flag-A20 plasmid was provided by Dr. Adrian Ting (Mount Sinai School of Medicine). The construction of all other plasmids is described in the Supplemental Experimental Procedures.
Antibodies
Antibodies against Flag (M2 and rabbit polyclonal, Sigma, St. Louis, MO), HA (HA.7 [Sigma] HA.11 [Covance Research, Berkeley, CA]), Ub (P4D1, Cell Signaling, Danvers, MA,) NF-kB p65 (F-6, Santa Cruz Biotech, Santa Cruz, CA), and actin (AC-74, Sigma) were used following manufacturer's protocol. Anti-mouse ISG15 monoclonal (3C2 and 2D12) and polyclonal antibodies and antiserum recognizing EAV-nsp2 (Snijder et al., 1994) have been previously described.
Purification of CCHFV L(1-169) from E. coli BL-21 cells (Stratagene, La Jolla, CA) were transformed with pGEX-L(1-169) or pGEX-L(1-169)1A CCHFV, cultured to an OD 600 of 0.6 in 2xYT medium and induced for 6 hr at 30 C with 0.1 mM IPTG. Bacteria were resuspended in lysis buffer (50 mM Tris-HCl, 5 mM EDTA, 1 mM DTT, 200 mM NaCl, and 0.1% NP-40), and purification of the GST fusion proteins was performed using GSH Sepharose resin (Amersham) according to the manufacturer's protocol. GST was cleaved using PreScission Protease (Pharmacia, Uppsala, Sweden) in cleavage buffer (50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1 mM EDTA, and 1 mM DTT).
Assays for DeISGylation in Cultured Cells
Initially, 293T cells cultured in 12-well dishes were cotransfected with 0.4 mg of pCAGGS-6HismISG15, 0.4 mg of pCAGGS-hUBE1L-HA, and 0. 
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Evasion of Ubiquitin-and ISG15-Dependent Immunity subsequent experiments testing eukaryotic and viral OTU constructs, 293T cells in 12-well dishes were cotransfected with OTU domain expression plasmids and 0.5 mg pCAGGS-6His mISG15, 0.5 mg pCAGGS-mUBE1L-HA, 0.5 mg of plasmid encoding Herc5, and 0.2 mg pFLAGCMV2 UbcM8 or pCDNA3.1-UbcM8. Twenty-four hours posttransfection, cells were lysed in Laemmli sample buffer, boiled, and analyzed by immunoblot using anti-ISG15 mAb 3C2 as previously described . Each transfection experiment was performed a minimum of three times.
Assay for Deubiquitination in Cultured Cells
293T cells cultured in 12-well dishes were cotransfected with 0.5 mg of pcDNA3.1-HA-Ub and various OTU domain expression plasmids or empty pCAGGS plasmid using Lipofectamine 2000. Twenty-four hours posttransfection, the cells were lysed in Laemmli sample, boiled, and immunoblotted with anti-HA antibody. Each transfection experiment was performed a minimum of three times.
Generation of ISG15 Conjugates
Fourteen 10 cm dishes of 293T cells were transfected with 6 mg pCAGGS-6HismISG15, 3 mg pCAGGS-hUBE1L-HA, and 3 mg pFLAGCMV2-UbcM8. Twenty-four hours later, cells were harvested, resuspended in 20 mM Tris-HCl (pH 8.0) with 300 mM NaCl, and lysed by three cycles of freeze-thaw. Lysates were centrifuged for 15 min at 14,000 rpm. His-tagged ISG15 conjugates were purified over a His-Select Spin Column (SIGMA) following the manufacturer's directions. Column-bound conjugates were washed extensively with washing buffer , 300 mM NaCl, and 5 mM Imidazole) and eluted with 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, and 250 mM Imidazole. Protein concentration was measured by Bradford assay (Bio-Rad).
In Vitro Deconjugation Assays K 48 Ub 2-7 , K 63 Ub 3-7 , SUMO-2 2-8 , SUMO-3 2-8 , pro-ISG15, pro-Nedd8, pro-SUMO-1, USP5/Isopeptidase T, NEDP1, UBP43, A20 CD , and His6-SENP2 CD were purchased from Boston Biochem (Cambridge, MA). All reactions were performed in 50 mM Tris-HCl (pH 7.6), 5 mM MgCl2, and 2 mM DTT at 37 C for 2 hr. Serial 10-fold dilutions of L or L(1-169)1A (ranging from 2.5 mM to 2.5 nM) were incubated with either 2.5 mg Ub chains or SUMO chains; 2.5 mg pro-ISG15, pro-Nedd8, or pro-SUMO-1; 10 ml Ubp43 À/À lysate; or 3 mg of 6HisISG15 conjugates. Positive control for deconjugation was incubation with 100 mM USP5 (Ub), SENP2 CD (SUMO), NEDP1 (Nedd8), or UBP43 (ISG15). Negative control was incubation of chains or conjugates in assay buffer alone. Reactions were terminated by addition of Laemmli sample buffer and separated by SDS-PAGE electrophoresis on a 4%-20% gradient gel (BioRad). Proteins were visualized by SimplyBlue Safestain (Invitrogen) staining (Ub and SUMO) or by anti-ISG15 western blot.
Viruses
Sindbis viruses were generated from a cDNA clone by in vitro transcription and RNA transfection of BHK-21 cells as previously described (Levine et al., 1996; Lenschow et al., 2005) . Recombinant virus stocks were produced and titered on BHK-21 cells as previously described . Sindbis virus AR86 was a kind gift of Dr. Mark Heise (University of North Carolina, Chapel Hill) (Heise et al., 2000) .
NF-kB Reporter Gene Assay
293T cells were cotransfected with 3.3-fold dilutions (starting at 100 ng) of A20, CCHFV-L(1-169), CCHFV-L(1-169)2A, EAV-nsp2N, or empty plasmid along with the firefly luciferase gene construct under the control of the NF-kB-binding sites) (Wang et al., 2000) and pRL-TK (Renilla luciferase; Promega, WI). The total amount of transfected DNA was kept constant by adding the pCAGGS empty vector. Twenty-four hours posttransfection, the cells were stimulated with TNFa (10 ng/ml) for 6 hr, and luciferase activities were measured using the Dual-Luciferase Reporter (DLR) Assay System (Promega). Final NF-kB luciferase values were normalized with the Renilla luciferase values as internal control.
Immunofluorescence
Two hundred nanograms of empty plasmid or Flag-tagged L and L(1-169)2A were transfected into A549 cells. Twenty-four hours later, cells were stimulated with 10 ng/ml TNFa for 2 hr. Cells were fixed and permeabilized for 30 min at room temperature with 2.5% formaldehyde and 0.5% Triton X-100, washed extensively with PBS, and stained with anti-p65 and anti-Flag antibodies. Following PBS washes, cells were stained with anti-mouse (p65) or anti-rabbit (Flag) and secondary antibodies, and then mounted in medium containing an antifade reagent. Nuclear localization of p65 was scored in 100 to 400 transfected cells for each experimental condition.
Mouse Studies
IFNabR À/À mice on the 129/SV/Pas background were initially obtained from M. Aguet, Swiss Institute of Experimental Cancer Research (Epalinges, Switzerland) (Behr et al., 2001; Dunn et al., 2005) . CCHFV-L(1-1325) transgenic mice were generated at the WUSM Pathology Microinjection Core by microinjecting a linearized construct derived from pCAGGS-HA-L(1-1325) into B6 oocytes. Oocytes were implanted into pseudopregnant mice, and resulting litters were genotyped using PCR (primer sequences available upon request). Individual embryo MEFs from transgenic lines 1836, 1854, and 2929 were generated as described previously (Weck et al., 1999) . Uninfected transgenic brain was homogenized in 1 ml of DMEM with protease inhibitors using 100 ml 1.0 mm diameter zirconia-silica beads in a MagNa Lyser (Roche, Indianapolis, IN). To assess transgene expression, 4 3 10 5 MEFs or 12 ml of brain homogenate were immunoblotted with HA.11 and anti-actin antibodies. Eight-to ten-week-old male IFNabR À/À mice were infected subcutaneously (s.c.) in the left hind footpad with 5 3 10 6 PFU of virus diluted in 50 ml of Hank's balanced salt solution (HBSS). Four-to fiveweek old L(1-1325) transgenic mice were infected s.c. in the left hind footpad with 5000 PFU of Sindbis virus AR86 diluted in 50 ml of HBSS. Mice were bred and maintained at Washington University School of Medicine in accordance with all federal and university guidelines.
Statistical Analysis
All data were analyzed with Prism software (GraphPad, San Diego, CA). Survival data were analyzed by the log-rank (Mantel-Haenzsel) test, with death as the primary variable. Single-step growth curves were analyzed by one-way analysis of variance (ANOVA).
Supplemental Data
The Supplemental Data include Supplemental Experimental Procedures and two supplemental figures and can be found with this article online at http://www.cellhostandmicrobe.com/cgi/content/full/2/6/ 404/DC1/.
